Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
Yi Li,1,* Yizhao Xie,1,* Chengcheng Gong,1 Yannan Zhao,1 Jian Zhang,1 Sheng Zhang,1 Leiping Wang,1 She Chen,2 Xichun Hu,1 Biyun Wang1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, People&...
Saved in:
Main Authors: | Li Y (Author), Xie Y (Author), Gong C (Author), Zhao Y (Author), Zhang J (Author), Zhang S (Author), Wang L (Author), Chen S (Author), Hu X (Author), Wang B (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023) -
The Effectiveness of Fulvestrant in postmenopausal advanced breast cancer; systematic review of clinical evidence
by: Amir Hashemi-Meshkini, et al.
Published: (2015) -
Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World
by: Zhang L, et al.
Published: (2020) -
Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution
by: Maria Inês Teodoro, et al.
Published: (2024) -
Exemestane in early breast cancer: a review
by: Michael Untch, et al.
Published: (2008)